Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.

被引：0
|
作者：
Shevrin, Daniel H.
Symanowski, James Thomas
Shore, Neal D.
Lin, Daniel W.
Russell, David
Kral, Pavol
Song, Yi
El-Chaar, Nader N.
Karsh, Lawrence Ivan
机构：
[1] NorthShore Univ Hlth Syst, Glencoe, IL USA
[2] Atrium Hlth, Levine Canc Inst, Dept Biostat, Charlotte, NC USA
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Univ Washington, Inst Prostate Canc Res IPCR, Dept Urol, Seattle, WA USA
[5] Pfizer Inc, New York, NY USA
[6] IQVIA Inc, Bratislava, Slovakia
[7] Astellas Pharma Inc, Northbrook, IL USA
[8] Urol Ctr Colorado, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17085
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage
    Loriot, Yohann
    Fizazi, Karim
    EUROPEAN UROLOGY FOCUS, 2024, 10 (04): : 511 - 513
  • [12] Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer
    Wang, Zhipeng
    Liu, Haoyang
    Zhu, Qiyu
    Chen, Junru
    Zhao, Jinge
    Zeng, Hao
    BMC CANCER, 2024, 24 (01)
  • [13] CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES OF AFRICAN AMERICAN VERSUS CAUCASIAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF TRUMPET REGISTRY
    Clara, Hwang
    James, Symanowski
    Neal, Shore
    David, Russell
    Pavol, Kral
    Dina, Elsouda
    Nader, El-Chaar
    Lawrence, Karsh
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [14] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [15] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Marit A. C. Vermunt
    Merel van Nuland
    Lisa T. van der Heijden
    Hilde Rosing
    Jos. H. Beijnen
    Andries M. Bergman
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 785 - 793
  • [16] Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer
    Tashiro, Kojiro
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Urabe, Fumihiko
    Fukuokaya, Wataru
    Mori, Keiichiro
    Aikawa, Koichi
    Murakami, Masaya
    Sasaki, Hiroshi
    Miki, Kenta
    Miki, Jun
    Shimomura, Tatsuya
    Yamada, Hiroki
    Hata, Kenichi
    Nishikawa, Hideomi
    Abe, Hirokazu
    Watanabe, Ken
    Kimura, Takahiro
    CLINICAL GENITOURINARY CANCER, 2024, 22 (03)
  • [17] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Vermunt, Marit A. C.
    van Nuland, Merel
    van der Heijden, Lisa T.
    Rosing, Hilde
    Beijnen, Jos H.
    Bergman, Andries M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (06) : 785 - 793
  • [18] HTA and Reimbursement Status of Metastatic Hormone-Sensitive Prostate Cancer, Nonmetastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
    Bencina, Goran
    Petrova, Elina
    Sonmez, Demet
    Pereira, Sonia Matos
    Dimitriadis, Ioannis
    Salomonsson, Stina
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2023, 10 (01): : 102 - 110
  • [19] Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).
    Robin, Gabrielle
    Basappa, Naveen S.
    North, Scott A.
    Ghosh, Sunita
    Kolinsky, Michael Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [20] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
12345